ClearUP Product Line Improvements
Achieved over 70% gross margin on ClearUP sales post-restructuring, up from 40%-50% previously, and a significant improvement from a negative gross margin two years ago.
Cost Management Success
Operating expenses reduced to $1.5 million from $1.9 million last year, contributing to a 20% reduction in year-over-year net operating loss.
Vagus Nerve Stimulation Program Progress
Completed Phase I trial with industry-leading data, optimization study enrollment, and identified top use cases for the technology with the help of Fletcher State.
Financial Leadership Transition
Lisa Wolf joined as interim CFO, bringing over 30 years of financial leadership experience, including public and private finance.